Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pactiv Evergreen (NASDAQ:PTVE) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.0, a high estimate of $19.00, and a low estimate of $13.00. Witnessing a positive shift, the current average has risen by 37.1% from the previous average price target of $11.67.
Interpreting Analyst Ratings: A Closer Look
The perception of Pactiv Evergreen by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Curt Woodworth | UBS | Announces | Buy | $19.00 | - |
| Anthony Pettinari | Citigroup | Raises | Buy | $16.00 | $10.00 |
| George Staphos | B of A Securities | Raises | Buy | $16.00 | $14.00 |
| Arun Viswanathan | RBC Capital | Raises | Outperform | $13.00 | $11.00 |
Key Insights:
Capture valuable insights into Pactiv Evergreen's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Pactiv Evergreen analyst ratings.
Discovering Pactiv Evergreen: A Closer Look
Key Indicators: Pactiv Evergreen's Financial Health
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Pactiv Evergreen's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2023, the company experienced a revenue decline of approximately -14.29%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 2.1%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Pactiv Evergreen's ROE excels beyond industry benchmarks, reaching 2.25%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Pactiv Evergreen's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.44%, the company showcases efficient use of assets and strong financial health.
Debt Management: Pactiv Evergreen's debt-to-equity ratio is below the industry average at 3.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
